RT Journal Article
SR Electronic
T1 Ayahuasca-Inspired DMT/HAR Formulation Reduces Brain Differentiation Between Self and Other Faces
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.28.24316308
DO 10.1101/2024.10.28.24316308
A1 Suay, Dila
A1 Aicher, Helena D.
A1 Kometer, Micheal
A1 Mueller, Michael J.
A1 Caflisch, Luzia
A1 Hempe, Alexandra
A1 Steinhart, Camilla P.
A1 Elsner, Claudius
A1 Wicki, Ilhui A.
A1 Müller, Jovin
A1 Meling, Daniel
A1 Dornbierer, Dario A.
A1 Scheidegger, Milan
A1 Bottari, Davide
YR 2024
UL http://medrxiv.org/content/early/2024/11/01/2024.10.28.24316308.abstract
AB Background Psychedelics are known to profoundly alter perception and self-referential processing, yet their specific effects on face recognition—a key aspect of social cognition—remain underexplored.Objective This study investigates the effects of an ayahuasca-inspired novel DMT/HAR (N,N-dimethyltryptamine/Harmine) formulation and Harmine alone on face recognition and self-referential processing, as measured by event-related potentials (ERPs).Methods In a within-subject, double-blind, placebo-controlled design, 31 healthy male participants underwent EEG recording during a visual oddball task involving Self, Familiar, and Unknown Faces. The study compared the effects of a DMT/HAR formulation, harmine alone, and placebo on key visual ERP components: P1, N170, and P300.Results DMT/HAR increased P1 amplitude and decreased N170 amplitude across all face categories, indicating enhanced early visual processing and disrupted face structural encoding. DMT/HAR also reduced P300 amplitude specifically for self-faces, diminishing neural differentiation between self and other faces.Conclusion The DMT/HAR formulation significantly blurs the neural distinction between self and other faces, suggesting a potential mechanism by which psychedelics diminish attentional focus on self-referential information, thereby enhancing empathy and unity. These insights into serotonergic modulation of face recognition could inform therapeutic strategies for disorders characterized by altered self-processing.Competing Interest StatementMS, MK and DAD co-founded Reconnect Labs, an academic spin-off at the University of Zurich. MJM is a shareholder of Reconnect Labs. All other co-authors have no conflict of interest to declare related to this work.Clinical TrialNCT04716335Funding StatementWe gratefully acknowledge grant funding that supported this publication from a Frontiers Proposal Fellowship of the IMT School for Advanced Studies (D. Suay, 2021/2022), Italian Ministry of University and Research (D. Bottari, MUR; PRIN 2017 research grant. Prot. 20177894ZH), private donations of Fabian Hediger (M. J. Muller), the SNSF Swiss National Science Foundation (H. D. Aicher, Doc.CH Grant P0ZHP1_191935; M. Scheidegger & D. Meling, Spark CRSK-1_196833; D. A. Dornbierer, BRIDGE PoC 40B1-0_198689), from the Bioentrepreneur Fellowship UZH (D.A. Dornbierer, BIOEF-18-009), from the Forschungskredit PostDoc UZH (M. Scheidegger, Grant No. FK-18-052). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of University of Zurich gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors